Company intelligence / Profile preview

Kenox Pharmaceuticals

South Plainfield, New Jersey, United Stateskenoxpharma.us ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

Kenox has demonstrated success advancing innovative orally-inhaled and nasal drug products from early R&D through clinical manufacturing. Notably, their KNX018 program received positive FDA feedback at pre‑IND stage for use as an adjuvant in NSCLC radiation therapy. They also collaborate on novel biologic delivery systems such as intranasal sIgA therapies.

Therapeutic areas: PulmonologyOncologyRare DiseasesImmunologyPsychiatryCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculesBiologicsDrug-device combinations
Industry: Contract Research Organization

Partnerships

Lactiga US Inc.Multiple undisclosed pharma/biotech clients utilizing CDMO/CRO services

Beyond the preview

Go deeper on Kenox Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kenox Pharmaceuticals.

Explore the full profile